Klinikum Fulda gAG
- Address
- Pacelliallee 4, Ziehers-Sued, 36043 Fulda, Germany
Digestive System Diseases
The department is conducting innovative studies on conditions of the gastrointestinal tract, aiming to test new targeted medicines, microbiome‑based therapies, and surgical‑preserving approaches.
- Evaluation of a targeted therapy for moderate to severe Crohn’s disease
- Long‑term encapsulated stool microbiome transfer for active ulcerative colitis
- Adjuvant treatment guided by ctDNA status after resection of colon cancer stage II
- Organ‑preserving strategy for intermediate and high‑risk rectal cancer
Klinikum Fulda gAG is strengthening digestive health research with a focus on patient‑centered outcomes.
Hemic and Lymphatic Diseases
Trials in this area explore novel combinations of kinase inhibitors, immunotherapies, and antibody‑based regimens to improve survival and reduce treatment toxicity for blood‑related cancers.
- Tyrosine‑kinase inhibitor plus chemotherapy versus standard care for acute lymphoblastic leukemia with Philadelphia chromosome
- Reduced‑toxicity BrECADD regimen compared with escalated BEACOPP in Hodgkin lymphoma
- Isatuximab addition to RVd induction and maintenance in newly diagnosed multiple myeloma
- Comparison of induction and maintenance strategies to achieve MRD negativity in acute lymphoblastic leukemia
The site’s hematology‑oncology team contributes valuable data to international blood‑cancer studies.
Immune System Diseases
Research focuses on autoimmune kidney disorders and fibrotic lung disease, evaluating agents that aim to lower proteinuria and improve lung function while clarifying underlying immune mechanisms.
- Assessment of ALXN2050 for proteinuria reduction in lupus nephritis and IgA nephropathy
- Dose‑response exploration of BI 1819479 in patients with idiopathic pulmonary fibrosis
- Mechanistic profiling of targeted therapies influencing immune pathways in renal disease
Klinikum Fulda gAG’s immunology program aims to bring safer, more effective treatments to patients with autoimmune conditions.
Neoplasms
The oncology unit investigates both solid tumors and hematologic malignancies, seeking to refine adjuvant strategies, preserve organ function, and integrate novel antibodies into standard regimens.
- ctDNA‑guided adjuvant therapy after resection of colon cancer stage II
- Selective organ preservation versus conventional chemoradiotherapy for rectal cancer
- Isatuximab combined with RVd induction and lenalidomide maintenance in multiple myeloma
- Evaluation of combined chemoradiotherapy outcomes in high‑risk rectal cancer
The multidisciplinary cancer center at Klinikum Fulda gAG drives progress across a spectrum of tumor types.
Respiratory Tract Diseases
Studies target fibrotic lung disease, aiming to identify optimal dosing and demonstrate functional improvement with emerging anti‑fibrotic agents.
- Phase‑focused dose‑finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
- Quantitative assessment of lung‑function change following experimental therapy
- Exploration of biomarker‑driven response patterns in fibrotic lung disease
The site leverages its pulmonary expertise to advance treatment options for severe respiratory disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Goethe University Frankfurt1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Goethe University Frankfurt2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Fulda gAG
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 2 | Unknown | 2019-12-04 | 2020-03-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.